H-TYPE HYPERTENSION GENE FOLATE: CHINA STROKE PRIMARY PREVENTION TRIAL

摘要

Hypertension, as a major modifiable risk factor for CVDs, is fairly common among adults in China. The treatment and control of prevalent hypertension have been improved in many high-income countries. By contrast, although the treatment and control rates of hypertension have increased, it remains unacceptably low in China. This symposium consists of four abstracts which will mainly deal with the trend in the prevalence of hypertension as well as in the treatment and control rates of prevalent hypertension. The first one will discuss the controversies related to folic acid supplementation in cardiovascular disease and stroke, focusing on the new evidence of effect of folic acid therapy on incident stroke and key genetic and nutrition modification. Another talk will provide an overview of recent advances in this field; highlight the findings from a sub-study of the China Stroke Primary Prevention Trial (CSPPT) and focus on the effect of folic acid therapy on renal endpoints. The third presentation will discuss the perennial interest in and debate on blood pressure control targets and the notion of a “J” shaped curve. It will also present findings from several groundbreaking studies in eastern and western populations. The last presentation will describe the MTHFR C677T gene polymorphism and the concept of gene-nutrition interaction and illustrate the concept by presenting the findings from the CSPPT, which has clearly demonstrated the interactive effect of MTHFR C677T polymorphism and folic acid on serum homocysteine (Hcy) levels and lowering in response to folic acid therapy among Chinese hypertensive adults.